您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > SKI II
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
SKI II
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
SKI II图片
CAS NO:312636-16-1
包装与价格：
包装价格(元)
10 mM * 1 mL in DMSO电议
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
200mg电议
500mg电议
1 g电议

产品介绍
SKI II 是一种合成的、口服有效的鞘氨醇激酶 (SK)抑制剂, 抑制 SK1 和 SK2,IC50值分别为 78 μM 和 45 μM。SKI II 通过诱导溶酶体和/或蛋白酶体降解导致SK1的不可逆抑制。
生物活性

SKI-II is an oral active and synthetic inhibitor ofsphingosine kinase (SK)activity, withIC50values of 78 μM and 45 μM for SK1 and for SK2, respectively. SKI II causes an irreversible inhibition of SK1 by inducing its lysosomal and/or proteasomal degradation[1][2].

IC50& Target

IC50 value: 78/45 μM (SK1/2)[1][2].

体外研究
(In Vitro)

SKI II inhibits cell proliferation by suppressing the Wnt/β-catenin signaling pathway. SKI II promotes the degradation of β-catenin by enhancing Wnt5A[1].
SKI II (1.25 μM, 48 h) in combination with DDP has a clear synergistic effect in human gastric carcinoma SGC7901/DDP cell line[2].

Cell Cytotoxicity Assay[1]

Cell Line:The human gastric carcinoma SGC7901/DDP cell line.
Concentration:0 μM, 1.25 μM (combined with DDP).
Incubation Time:48 hours.
Result:SKI II in combination with DDP had a greater effect on the SGC-7901/DDP cells compared with DDP or SKI II alone.
体内研究
(In Vivo)

Chronic SKI II (50.0 mg/kg, 3-weekly i.p. for 16 weeks) administration leads to permanent reduction of S1P concentrations in plasma in mice[3].
SKI II (50.0 mg/kg, IP; 100 mg/kg, PO) treatment reduces tumor growth in mice bearing solid tumor model[4].

Animal Model:8 week-old female LDL-R-/-mice[3].
Dosage:50.0 mg/kg.
Administration:IP injection daily, 3 days a week for 16 weeks.
Result:A single administration of produced a significant reduction of plasma S1P with the maximum (~40%) observed 12 h after injection. At sacrifice (72 h after last injection) S1P levels were 266 ± 18 ng/mL and 328 ± 30 ng/mL in the SKI-II-treated and control groups, respectively.
Animal Model:BALB/c mouse solid tumor model that uses JC mammary adenocarcinoma cells[4].
Dosage:50.0 mg/kg.
Administration:IP injection daily, 3 days a week for 16 weeks.
Result:Had strong inhibition of tumor growth from the start of treatment of 65%, with no toxicity or weight loss.
Animal Model:BALB/c JC tumor model[4].
Dosage:100 mg/kg.
Administration:PO every other day.
Result:Caused significant antitumor activity in well-established tumors as early as day 5, with maximal response seen at the end of the study. Showed 79% inhibition of tumor growth from the start of treatment.
分子量

302.78

性状

Solid

Formula

C15H11ClN2OS

CAS 号

312636-16-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder-20°C3 years
4°C2 years
In solvent-80°C6 months
-20°C1 month
溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL(330.27 mM)

*"≥" means soluble, but saturation unknown.

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM3.3027 mL16.5136 mL33.0273 mL
5 mM0.6605 mL3.3027 mL6.6055 mL
10 mM0.3303 mL1.6514 mL3.3027 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40%PEG300   5%Tween-80   45% saline

    Solubility: ≥ 2.75 mg/mL (9.08 mM); Clear solution

    此方案可获得 ≥ 2.75 mg/mL (9.08 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH2O 中，得到澄清透明的生理盐水溶液
  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20%SBE-β-CDin saline)

    Solubility: ≥ 2.75 mg/mL (9.08 mM); Clear solution

    此方案可获得 ≥ 2.75 mg/mL (9.08 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
*以上所有助溶剂都可在本网站选购。